Assignee
NACUITY PHARMACEUTICALS INC
US·10 granted patents·15 pending applications·28 citations·filing 2015–2025
Top patents by PatentIndex Score
25 records- 0192US11548851B2Method for preparation of n-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2021·Granted Jan 10, 2023·3 cites·17 claims
- 0292US11091433B2Method for preparation of N-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Aug 17, 2021·4 cites·29 claims
- 0392US9889103B2Method for the preparation of N-acetyl cysteine amideNACUITY PHARMACEUTICALS INC·Filed 2017·Granted Feb 13, 2018·8 cites·20 claims
- 0492US9763902B2Method for preparation of N-acetyl cysteine amideNACUITY PHARMACEUTICALS INC·Filed 2015·Granted Sep 19, 2017·8 cites·20 claims
- 0587US10590073B2Method for preparation of N-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·5 cites·25 claims
- 0668US2024368072A1Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivativesNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0766US2024217927A1Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0865US11753370B2Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stressNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Sep 12, 2023·0 cites·7 claims
- 0965US2023373913A1Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1064US2023381120A1Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)NACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1163US2024342118A1Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivativesNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1260US2024008971A1Ophthalmic ImplantNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1359US2022304955A1Treatment of ferroptosisNACUITY PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1459US2026014102A1Treatment of retinitis pigmentosa and retinitis pigmentosa associated with usher syndrome with n-acetylcysteine amideNACUITY PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1559US2023159448A1Method for Preparation of N-Acetyl Cysteine Amide and Derivatives ThereofNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1659US2026083688A1N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis PigmentosaNACUITY PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1758US12458608B2N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvementNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Nov 4, 2025·0 cites·17 claims
- 1857US12245998B2N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic FibrosisNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 1952US11766413B2Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)NACUITY PHARMACEUTICALS INC·Filed 2020·Granted Sep 26, 2023·0 cites·17 claims
- 2052US2021228509A1Prodrug for the treatment of disease and injury of oxidative stressNACUITY PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2152US2025235416A1Method for preparation of n-acetyl cysteine amide, derivatives and tablets thereofNACUITY PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2251US2021378993A1Treatment of cystinosisNACUITY PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2350US2019135741A1Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2447US2020217852A1Quantitation of Free and Total N-Acetylcysteine Amide and Its Metabolite N-Acetylcysteine in Human Plasma Using Derivatization and Electrospray LC-MS/MSNACUITY PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2536US12472157B2Treatment of retinitis pigmentosa with n-acetylcysteine amideNACUITY PHARMACEUTICALS INC·Filed 2015·Granted Nov 18, 2025·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when NACUITY PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →